

RESEARCH ARTICLE

Synthesis and anti-cancer activity evaluation of new aurone derivatives

Seref Demirayak¹, Leyla Yurttas², Nalan Gundogdu-Karaburun², Ahmet Cagri Karaburun², and Ismail Kayagil³

¹Department of Pharmaceutical Chemistry, School of Pharmacy, Medipol University, Istanbul, Turkey, ²Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskisehir, Turkey, and ³Department of Chemistry, Faculty of Arts & Science, Mehmet Akif Ersoy University, Burdur, Turkey

Abstract

In this study, we have synthesized 2-[3- or 4-(2-aryl-2-oxoethoxy)arylidene]benzofuran-3-one derivatives (**D1–D38**) and evaluated their anti-cancer activities. The final compounds were obtained in multistep synthesis reactions using benzofuranon-3-one derivatives (**A1–A4, B**) as starting materials which were gained in various synthetic ways. Aurone derivatives (**C1–C10**) were acquired with the condensation reaction of these starting materials and 3-/4-hydroxybenzaldehyde which were then reacted with α -bromoacetophenones to get final compounds. The anti-cancer activity of the selected compounds was performed by National Cancer Institute (NCI), USA against 60 human tumor cell lines derived from nine neoplastic diseases. Compounds exhibited anti-cancer activity in varying ratios.

Keywords

Anti-cancer activity, aurone, benzofuranone, NCI, synthesis

History

Received 22 August 2014

Revised 9 October 2014

Accepted 10 October 2014

Published online 6 January 2015

Introduction

Flavonoids are secondary metabolites of plants which exhibit various biological properties that are beneficial for human health via interacting with some cellular targets in the body. They can be classified into several subclasses and some of these subclasses are flavonols, flavones, isoflavones, flavanones, flavans, aurones and chalcones^{1,2}. All classes of flavonoids exhibit variety of biological and pharmacological activities, but among them, the chalcones (Figure 1a) and their ring analogue flavones (Figure 1b) have been considerably explored. Various natural, semi-synthetic and synthetic derivatives of these structures have been investigated and reported with a wide range of biological applications^{3,4}.

Aurones, (Z)-2-benzylidenbenzofuran-3-(2H)-ones (Figure 1c), constitute a less studied subclass of flavonoids although they are isosteres of flavones^{5,6}. However, they have attracted attention with promising biological potential such as anti-microbial⁷, anti-cancer⁸, anti-leishmanial^{9–11}, anti-histaminic¹², anti-inflammatory¹³, antioxidant¹⁴, insect anti-feedant¹⁵, herbicidal¹⁶, anti-HIV^{17,18}, anti-HCV (hepatitis C virus)^{19,20}, anti-malarial^{21,22}, ChE inhibitory^{23,24}, MAO inhibitory²⁵ activities in the specified studies. The observed biological potential is thought to be due to the similarity of adenine of ATP and the flavonoids, consequently inhibition of the activity of ATP-dependent enzymes and proteins, which is essential for the function of enzymes and receptors. In particular, the aurones are estimated to mimic better the adenine because of the benzofuranone structure than the benzopyranone part of the corresponding flavones²⁶. Some naturally occurring aurones maritimein, sulfuretin and aureusidin are also studied and among them sulfuretin (Figure 1d) has been known to have anti-inflammatory activity^{27,28}. In recent years, flavonoids have been

developed as anti-cancer agents and have interested medicinal chemists. In fact, some flavonoids have entered clinical trials such as flavopiridol which was identified as the first cyclin-dependent kinase inhibitor and entered phase II clinical trials^{29,30}. Among them, aurones have been first reported in 2003 with high anti-cancer activity and they were determined to exhibit higher cytotoxic property than corresponding chalcone and flavon derivatives at same concentrations³¹. In subsequent years, many studies were performed about the anti-cancer activity of the aurones^{32–39}. Along with the identified molecular mechanisms of flavonoids as carcinogen inactivation, anti-proliferation, cell cycle arrest, induction of apoptosis and differentiation, inhibition of angiogenesis, antioxidation and reversal of multidrug resistance; α,β -unsaturated carbonyl structure has been evaluated inducing anti-cancer activity with acting as an alkylating agent^{40–42}.

Considering literature findings and as a continuation of our on-going studies⁴³, we synthesized new aurone derivatives and evaluated their anti-cancer activity.


Experimental section

Chemistry

All reagents and solvents were obtained from Sigma-Aldrich Chemical Co (Sigma-Aldrich Corp., St. Louis, MO) and Merck KGaA (Darmstadt, Germany). Melting points were determined using a Electrothermal 9100 digital melting point apparatus (Essex, UK) and are uncorrected. All reactions were monitored by thin layer chromatography (TLC) using Silica Gel 60 F254 TLC plates (Merck KGaA, Darmstadt, Germany). Petroleum ether and ethyl acetate were used as mobile phase prepared in various ratios for TLC. Spectroscopic data were recorded as follows: IR spectra were IR Shimadzu 8400S FT-IR spectrometer (Tokyo, Japan), ¹H-NMR spectra on a Bruker 500 MHz spectrometer (Billerica, MA) in DMSO-*d*₆ with TMS as internal standard and mass

Address for correspondence: Leyla Yurttas, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskisehir, Turkey. E-mail: lyurttas@anadolu.edu.tr

Figure 1. The chemical structures of (a) chalcone, (b) flavone, (c) aurone, (d) sulfuretin.



spectra using a Agilent 110 MSD spectrometer (Santa Clara, CA) instruments.

Benzofuran-3-one derivatives (A1–A4)

Phenole derivative (0.5 mol) (**R**: H, 5-methyl, 5-chloro, 6-methyl, 6-chloro) was first refluxed with acetic anhydride (0.6 mol) in pyridine for 30 min and then the reaction mixture was treated with water after cooling, the precipitated material was filtered or not solidified material was extracted with appropriate solvents. The obtained phenyl acetate derivative (**I**) (0.4 mol) was reacted with AlCl_3 (0.48 mol) in a flask placed in an oil bath kept under control at 160–170 °C. After exiting oil bath, viscous mixture was poured into ice water and dried up to get 2'-hydroxyacetophenone derivatives (**II**). Compound **II** (0.3 mol) was stirred with acetic anhydride (0.45 mol) at 50–100 °C for 3–4 h which was acetylated in order to prevent reaction ability of hydroxyl group. The obtained 2'-acetyloxyacetophenone derivatives (**III**) (0.25 mol) compound was brominated with Br_2 (0.3 mol) in ether or acetic acid to get 2'-acetyloxy-2-bromoacetophenone derivatives (**IV**) which was then hydrolyzed with 10% HCl acid (300 ml) to afford 2'-hydroxy-2-bromoacetophenone (**V**). Finally, compounds **A1**, **A2**, **A3** and **A4** (0.2 mol) were achieved from compound **V** and sodium acetate (0.6 mol) at reflux conditions in ethanol by a cyclization reaction. The intermediate products were gained by filtration from reaction medium which were then crystallized from petroleum ether. The obtained compounds and melting points indicated in the literature is given below.

Benzofuran-3-one (**A1**): 101–103 °C⁴⁴. 5-Methylbenzofuran-3-one (**A2**): 83–85 °C⁴⁵.

5-Chlorobenzofuran-3-one (**A3**): 87–89 °C⁴⁵. 6-Methylbenzofuran-3-one (**A4**): 83–85 °C⁴⁵.

6-Methoxybenzofuran-3-one (B)

Resorcinol was refluxed with dimethylsulfate and sodium hydroxide in acetone to give 1,3-dimethoxybenzene using standard procedures. The obtained compound was then reacted with chloroacetyl chloride and anhydrous aluminium chloride in carbon disulfide by Friedel-Crafts acetylation. The obtained 2'-hydroxy-4-methoxy-2-chloroacetophenone was reacted with sodium acetate in ethanol to give 6-methoxybenzofuran-3-one (**B**) m.p. 120–122 °C⁴⁶.

2-(3- or 4-Hydroxybenzylidene)benzofuran-3-one derivatives (C1–C10)

Benzofuranone derivative (20 mmol) (**A1–A4**, **B**) was refluxed with 3-/4-hydroxybenzaldehyde derivatives (22 mmol) in 70 mL

n-butanol or isobutanol for 1 h using hydrochloric acid as a catalyst (1 ml). The precipitate formed upon cooling was filtered and crystallized. The chemical properties of the obtained ten derivatives (**C1–C10**) were given in Table 1.

General procedure of the synthesis 2-[3- or 4-(2-aryl-2-oxoethoxy)arylidene]benzofuran-3-one derivatives (D1–D38)

2-(3- or 4-Hydroxybenzylidene)benzofuran-3-one derivatives (**C1–C10**) (3 mmol) were refluxed with brominated acetophenones (3 mmol) for 6 h in acetone with the presence of potassium carbonate (0.03 mmol). After TLC, the reaction solvent was evaporated and the obtained residue was washed with water and crystallized from ethanol to achieve 2-[3- or 4-(2-Aryl-2-oxoethoxy)arylidene]benzofuran-3-one compounds (**D1–D38**). The chemical properties of the obtained 10 derivatives (**D1–D38**) were given in Table 2.

2-[3-(2-Phenyl-2-oxoethoxy)benzylidene]benzofuran-3-one (D1)

IR (KBr) ν_{max} (cm⁻¹): 3098, 3046 (Aromatic C–H), 2975, 2945, 2844 (Aliphatic C–H), 1704, 1669 (C=O), 1602–1477 (C=C), 1288, 1217 (C–O). ¹H-NMR δ (ppm): 5.69 (2H, s, OCH₂), 6.93 (1H, s, =CH–), 7.11 (1H, dd, J: 1.48 Hz, J: 8.25 Hz, Ar-H), 7.29–7.33 (2H, m, Ar-H), 7.42–7.45 (2H, m, Ar-H), 7.58–7.66 (4H, m, Ar-H), 7.72–7.83 (2H, m, Ar-H), 8.08 (2H, d, J: 8.10 Hz, Ar-H). MS [M + 1]⁺: *m/z* 357.1.


2-[3-[2-(4-Methylphenyl)-2-oxoethoxy]benzylidene]benzofuran-3-one (D2)

IR (KBr) ν_{max} (cm⁻¹): 3074, 3035 (Aromatic C–H), 2975, 2834 (Aliphatic C–H), 1699, 1669 (C=O), 1598–1475 (C=C), 1275, 1234 (C–O). ¹H-NMR δ (ppm): 2.45 (3H, s, CH₃), 5.66 (2H, s, OCH₂), 6.95 (1H, s, =CH–), 7.17 (1H, dd, J: 1.34 Hz, J: 8.22 Hz, Ar-H), 7.29–7.36 (2H, m, Ar-H), 7.43 (2H, d, J: 8.35 Hz, Ar-H), 7.47 (1H, s, Ar-H), 7.60–7.68 (2H, m, Ar-H), 7.78–7.83 (2H, m, Ar-H), 8.00 (2H, d, J: 8.12 Hz, Ar-H). MS [M + 1]⁺: *m/z* 371.

2-[3-[2-(4-Methoxyphenyl)-2-oxoethoxy]benzylidene]benzofuran-3-one (D3)


IR (KBr) ν_{max} (cm⁻¹): 3077, 3039 (Aromatic C–H), 2960, 2862 (Aliphatic C–H), 1705, 1681 (C=O), 1647–1464 (C=C), 1271, 1224 (C–O). ¹H-NMR δ (ppm): 3.90 (3H, s, OCH₃), 5.63 (2H, s, OCH₂), 6.95 (1H, s, =CH–), 7.10 (1H, dd, J: 1.32 Hz, J: 8.41 Hz, Ar-H), 7.12 (2H, d, J: 7.05 Hz, Ar-H), 7.34 (2H, d, J: 7.30 Hz, Ar-H), 7.55 (1H, t, J: 8.20 Hz, Ar-H), 7.61–7.63 (2H, m, Ar-H),

Table 1. Some characteristics of the compounds (C1–C10).



C.	Chemical name	R	–OH	M.P. (°C)
C1	2-(3-Hydroxybenzylidene)benzofuran-3-one	H	3	195–196 ⁵¹
C2	2-(4-Hydroxybenzylidene)benzofuran-3-one	H	4	261–262 ⁵¹
C3	5-Methyl-2-(3-hydroxybenzylidene)benzofuran-3-one	5-CH ₃	3	221–222
C4	5-Methyl-2-(4-hydroxybenzylidene)benzofuran-3-one	5-CH ₃	4	263–264 ⁵²
C5	6-Methyl-2-(3-hydroxybenzylidene)benzofuran-3-one	6-CH ₃	3	195–197
C6	6-Methyl-2-(4-hydroxybenzylidene)benzofuran-3-one	6-CH ₃	4	250–252
C7	6-Methoxy-2-(3-hydroxybenzylidene)benzofuran-3-one	6-OCH ₃	3	220–222 ⁵³
C8	6-Methoxy-2-(4-hydroxybenzylidene)benzofuran-3-one	6-OCH ₃	4	219–220 ⁵³
C9	5-Chloro-2-(3-hydroxybenzylidene)benzofuran-3-one	5-Cl	3	199–201
C10	5-Chloro-2-(4-hydroxybenzylidene)benzofuran-3-one	5-Cl	4	270–272

Table 2. Some characteristics of the compounds (D1–D38).



Compound	-R	-R'	Position	M.P. (°C)	M.F.
D1	-H	-H	3	150–151	C ₂₃ H ₁₆ O ₄
D2	-H	-CH ₃	3	162–162	C ₂₄ H ₁₈ O ₄
D3	-H	-OCH ₃	3	135–136	C ₂₄ H ₁₈ O ₅
D4	-H	-Cl	3	134–135	C ₂₃ H ₁₅ ClO ₄
D5	-H	-NO ₂	3	195–197	C ₂₃ H ₁₅ NO ₆
D6	-H	-H	4	150–152	C ₂₃ H ₁₆ O ₄
D7	-H	-CH ₃	4	186–188	C ₂₄ H ₁₈ O ₄
D8	-H	-OCH ₃	4	180–181	C ₂₄ H ₁₈ O ₅
D9	-H	-Cl	4	176–177	C ₂₃ H ₁₅ ClO ₄
D10	-H	-NO ₂	4	220–221	C ₂₃ H ₁₅ NO ₆
D11	5-CH ₃	-H	3	149–150	C ₂₄ H ₁₈ O ₄
D12	5-CH ₃	-OCH ₃	3	173–174	C ₂₅ H ₂₀ O ₅
D13	5-CH ₃	-Cl	3	159–161	C ₂₅ H ₁₇ ClO ₄
D14	5-CH ₃	-H	4	203–204	C ₂₄ H ₁₈ O ₄
D15	5-CH ₃	-OCH ₃	4	220–221	C ₂₅ H ₂₀ O ₅
D16	5-CH ₃	-Cl	4	226–227	C ₂₅ H ₁₇ ClO ₄
D17	6-CH ₃	-H	3	139–140	C ₂₄ H ₁₈ O ₄
D18	6-CH ₃	-OCH ₃	3	130–132	C ₂₅ H ₂₀ O ₅
D19	6-CH ₃	-Cl	3	179–181	C ₂₅ H ₁₇ ClO ₄
D20	6-CH ₃	-H	4	175–176	C ₂₄ H ₁₈ O ₄
D21	6-CH ₃	-OCH ₃	4	204–205	C ₂₅ H ₂₀ O ₅
D22	6-CH ₃	-Cl	4	209–210	C ₂₅ H ₁₇ ClO ₄
D23	6-OCH ₃	-H	3	136–137	C ₂₄ H ₁₈ O ₅
D24	6-OCH ₃	-CH ₃	3	172–173	C ₂₅ H ₂₀ O ₅
D25	6-OCH ₃	-OCH ₃	3	192–193	C ₂₅ H ₂₀ O ₆
D26	6-OCH ₃	-Cl	3	190–192	C ₂₄ H ₁₇ ClO ₅
D27	6-OCH ₃	-NO ₂	3	212–214	C ₂₄ H ₁₇ NO ₇
D28	6-OCH ₃	-H	4	197–199	C ₂₄ H ₁₈ O ₅
D29	6-OCH ₃	-CH ₃	4	185–187	C ₂₅ H ₂₀ O ₅
D30	6-OCH ₃	-OCH ₃	4	178–179	C ₂₅ H ₂₀ O ₆
D31	6-OCH ₃	-Cl	4	202–203	C ₂₄ H ₁₇ ClO ₅
D32	6-OCH ₃	-NO ₂	4	226–227	C ₂₄ H ₁₇ NO ₇
D33	5-Cl	-H	3	158–160	C ₂₃ H ₁₅ ClO ₄
D34	5-Cl	-OCH ₃	3	205–207	C ₂₄ H ₁₇ ClO ₅
D35	5-Cl	-Cl	3	199–200	C ₂₃ H ₁₄ Cl ₂ O ₄
D36	5-Cl	-H	4	214–216	C ₂₃ H ₁₅ ClO ₄
D37	5-Cl	-OCH ₃	4	196–198	C ₂₄ H ₁₇ ClO ₅
D38	5-Cl	-Cl	4	202–204	C ₂₃ H ₁₄ Cl ₂ O ₄

7.77–7.83 (2H, m, Ar-H), 8.07 (2H, d, J: 7.0 Hz, Ar-H). MS $[M + 1]^+$: m/z 387.

2-[3-[2-(4-Chlorophenyl)-2-oxoethoxy]benzylidene]benzofuran-3-one (D4)

IR (KBr) $\nu_{\max}$ (cm^{-1}): 3088, 3036 (Ar-H $\nu = \text{CH}-$), 2965, 2844 (Aliphatic C-H), 1706, 1665 (C=O), 1602–1477 (C=C), 1288, 1217 (C-O). $^1\text{H-NMR}$ δ (ppm): 5.79 (2H, s, OCH_2), 6.94 (1H, s, $=\text{CH}-$), 7.14 (1H, dd, J: 1.34 Hz, J: 8.22 Hz, Ar-H), 7.31–7.36 (2H, m, Ar-H), 7.58–7.63 (1H, m, Ar-H), 7.77–7.83 (2H, m, Ar-H), 7.72 (2H, d, J: 8.59 Hz, Ar-H), 7.83 (2H, d, J: 7.46 Hz, Ar-H), 8.10 (2H, d, J: 8.59 Hz, Ar-H). MS $[M + 1]^+$: m/z 390.5.

2-[3-[2-(4-Nitrophenyl)-2-oxoethoxy]benzylidene]benzofuran-3-one (D5)

IR (KBr) $\nu_{\max}$ (cm^{-1}): 3078, 3056 (Aromatic C-H), 2970, 2921, 2854 (Aliphatic C-H), 1697, 1649 (C=O), 1601–1478 (C=C, N=O), 1288, 1217 (C-O). $^1\text{H-NMR}$ δ (ppm): 5.75 (2H, s, OCH_2), 6.94 (1H, s, $=\text{CH}-$), 7.14 (1H, dd, J: 1.43 Hz, J: 8.26 Hz, Ar-H), 7.34 (1H, t, J: 7.50 Hz, Ar-H), 7.44–7.48 (2H, m, Ar-H), 7.63–7.67 (2H, m, Ar-H), 7.81 (2H, d, J: 7.52 Hz, Ar-H), 8.29 (2H, d, J: 8.73 Hz, Ar-H), 8.42 (2H, d, J: 8.68 Hz, Ar-H). MS $[M + 1]^+$: m/z 402.

2-[4-(2-Phenyl-2-oxoethoxy)benzylidene]benzofuran-3-one (D6)

IR (KBr) $\nu_{\max}$ (cm^{-1}): 3049, 3035 (Aromatic C-H), 2922, 2895 (Aliphatic C-H), 1709, 1693 (C=O), 1650–1479 (C=C), 1261, 1230 (C-O). $^1\text{H-NMR}$ δ (ppm): 5.64 (2H, s, OCH_2), 6.99 (1H, s, $=\text{CH}-$), 7.21 (2H, d, J: 8.70 Hz, Ar-H), 7.34 (1H, t, J: 7.50 Hz, Ar-H), 7.58 (2H, d, J: 8.84 Hz, Ar-H), 7.63 (2H, d, J: 7.65 Hz, Ar-H), 7.62–7.84 (2H, m, Ar-H), 8.0 (2H, d, J: 8.69 Hz, Ar-H), 8.07 (2H, d, J: 7.66 Hz, Ar-H). MS $[M + 1]^+$: m/z 357.2.

2-[4-[2-(4-Methylphenyl)-2-oxoethoxy]benzylidene]benzofuran-3-one (D7)

IR (KBr) $\nu_{\max}$ (cm^{-1}): 3084, 3025 (Aromatic C-H), 2972, 2832 (Aliphatic C-H), 1712, 1669 (C=O), 1622–1475 (C=C), 1275, 1234 (C-O). $^1\text{H-NMR}$ δ (ppm): 2.43 (3H, s, Ar-CH_3), 5.68 (2H, s, O-CH_2), 6.98 (1H, s, $=\text{CH}-$), 7.14 (2H, d, J: 8.60 Hz, Ar-H), 7.34 (1H, t, 7.43 Hz, Ar-H), 7.42 (2H, d, J: 7.93 Hz, Ar-H), 7.53 (1H, d, J: 8.61 Hz, Ar-H), 7.81–7.84 (2H, m, Ar-H), 7.97 (2H, d, J: 8.04 Hz, Ar-H), 8.0 (2H, d, J: 8.72 Hz, Ar-H). MS $[M + 1]^+$: m/z 371.

2-[4-[2-(4-Methoxyphenyl)-2-oxoethoxy]benzylidene]benzofuran-3-one (D8)

IR (KBr) $\nu_{\max}$ (cm^{-1}): 3070, 3032 (Aromatic C-H), 2965, 2844 (Aliphatic C-H), 1694, 1659 (C=O), 1598–1475 (C=C), 1275, 1224 (C-O). $^1\text{H-NMR}$ δ (ppm): 3.89 (3H, s, OCH_3), 5.65 (2H, s, OCH_2), 6.98 (1H, s, $=\text{CH}-$), 7.12 (2H, d, J: 7.77 Hz, Ar-H), 7.14 (2H, d, J: 7.78 Hz, Ar-H), 7.14 (1H, t, 7.40 Hz, Ar-H), 7.58 (1H, d, J: 8.58 Hz, Ar-H), 7.80–7.84 (2H, m, Ar-H), 7.77 (2H, d, J: 8.82 Hz, Ar-H), 8.0 (2H, d, J: 8.83 Hz, Ar-H). MS $[M + 1]^+$: m/z 387.

2-[4-[2-(4-Chlorophenyl)-2-oxoethoxy]benzylidene]benzofuran-3-one (D9)

IR (KBr) $\nu_{\max}$ (cm^{-1}): 3085, 3020 (Aromatic C-H), 2975, 2832 (Aliphatic C-H), 1710, 1670 (C=O), 1622–1475 (C=C), 1271, 1234 (C-O). $^1\text{H-NMR}$ δ (ppm): 5.66 (2H, s, OCH_2), 6.96 (1H, s, $=\text{CH}-$), 7.12 (2H, d, J: 7.90 Hz, Ar-H), 7.14 (1H, t, 7.40 Hz, Ar-H), 7.58–7.62 (1H, m, Ar-H), 7.66 (2H, d, J: 8.59 Hz,

Ar-H), 7.80–7.84 (2H, m, Ar-H), 7.94 (2H, d, J: 7.98 Hz, Ar-H), 8.10 (2H, d, J: 8.59 Hz, Ar-H). MS $[M + 1]^+$: m/z 390.5.

2-[4-[2-(4-Nitrophenyl)-2-oxoethoxy]benzylidene]benzofuran-3-one (D10)

IR (KBr) $\nu_{\max}$ (cm^{-1}): 3074, 3035 (Aromatic C-H), 2975, 2834 (Aliphatic C-H), 1699, 1669 (C=O), 1598–1475 (C=C, N=O), 1275, 1234 (C-O). $^1\text{H-NMR}$ δ (ppm): 5.76 (2H, s, OCH_2), 6.94 (1H, s, $=\text{CH}-$), 7.12 (2H, d, J: 7.90 Hz, Ar-H), 7.32–7.34 (1H, m, Ar-H), 7.44–7.48 (2H, m, Ar-H), 7.63–7.67 (1H, m, Ar-H), 7.80–7.84 (2H, m, Ar-H), 8.31 (2H, d, J: 8.82 Hz, Ar-H), 8.43 (2H, d, J: 8.84 Hz, Ar-H). MS $[M + 1]^+$: m/z 402.

2-[3-(2-Phenyl-2-oxoethoxy)benzylidene]-5-methylbenzofuran-3-one (D11)

IR (KBr) $\nu_{\max}$ (cm^{-1}): 3088, 3056 (Aromatic C-H), 2975, 2921, 2854 (Aliphatic C-H), 1702, 1664 (C=O), 1601–1477 (C=C), 1288, 1217 (C-O). $^1\text{H-NMR}$ δ (ppm): 2.35 (3H, s, CH_3), 5.68 (2H, s, OCH_2), 6.87 (1H, s, $=\text{CH}-$), 7.09 (1H, dd, J: 2.50 Hz, J: 8.23 Hz, Ar-H), 7.14 (1H, d, J: 8.91 Hz, Ar-H), 7.42 (2H, t, J: 8.0 Hz, Ar-H), 7.55–7.63 (5H, m, Ar-H), 7.74 (1H, t, J: 7.4 Hz, Ar-H), 8.08 (2H, d, J: 7.24 Hz, Ar-H). MS $[M + 1]^+$: m/z 371.

2-[3-(2-(4-Methoxyphenyl)-2-oxoethoxy)benzylidene]-5-methylbenzofuran-3-one (D12)

IR (KBr) $\nu_{\max}$ (cm^{-1}): 3053, 3012 (Aromatic C-H), 2918, 2841 (Aliphatic C-H), 1685, 1655 (C=O), 1601–1487 (C=C), 1275, 1238 (C-O). $^1\text{H-NMR}$ δ (ppm): 2.36 (3H, s, CH_3), 3.88 (3H, s, OCH_3), 5.58 (2H, s, OCH_2), 6.86 (1H, s, $=\text{CH}-$), 7.08 (1H, m, Ar-H), 7.11 (2H, d, J: 8.91 Hz, Ar-H), 7.16 (2H, d, J: 8.0 Hz, Ar-H), 7.41 (1H, t, J: 8.10 Hz, Ar-H), 7.54–7.56 (3H, m, Ar-H), 8.08 (2H, d, J: 7.24 Hz, Ar-H). MS $[M + 1]^+$: m/z 401.

2-[3-(2-(4-Chlorophenyl)-2-oxoethoxy)benzylidene]-5-methylbenzofuran-3-one (D13)

IR (KBr) $\nu_{\max}$ (cm^{-1}): 3077, 3029 (Aromatic C-H), 2987, 2860 (Aliphatic C-H), 1702, 1681 (C=O), 1621–1476 (C=C), 1274, 1223 (C-O). $^1\text{H-NMR}$ δ (ppm): 5.66 (2H, s, OCH_2), 6.86 (1H, s, $=\text{CH}-$), 7.10 (1H, dd, J: 2.30 Hz, J: 8.12 Hz, Ar-H), 7.22 (1H, d, J: 8.86 Hz, Ar-H), 7.42 (1H, t, J: 7.40 Hz, Ar-H), 7.54–7.62 (4H, m, Ar-H), 7.68 (2H, d, J: 8.54 Hz, Ar-H), 8.08 (2H, d, J: 8.54 Hz, Ar-H). MS $[M + 1]^+$: m/z 404.5.

2-[4-(2-Phenyl-2-oxoethoxy)benzylidene]-5-methylbenzofuran-3-one (D14)

IR (KBr) $\nu_{\max}$ (cm^{-1}): 3079, 3057 (Aromatic C-H), 2981, 2932, 2867 (Aliphatic C-H), 1703, 1666 (C=O), 1601–1477 (C=C), 1288, 1217 (C-O). $^1\text{H-NMR}$ δ (ppm): 2.34 (3H, s, CH_3), 5.70 (2H, s, OCH_2), 6.89 (1H, s, $=\text{CH}-$), 7.04 (2H, d, J: 8.15 Hz, Ar-H), 7.44–7.46 (3H, m, Ar-H), 7.48 (1H, s, Ar-H), 7.57–7.65 (2H, m, Ar-H), 7.72 (2H, d, J: 8.20 Hz, Ar-H), 8.05 (2H, d, J: 7.40 Hz, Ar-H). MS $[M + 1]^+$: m/z 371.

2-[4-(2-(4-Methoxyphenyl)-2-oxoethoxy)benzylidene]-5-methylbenzofuran-3-one (D15)

IR (KBr) $\nu_{\max}$ (cm^{-1}): 3058, 3010 (Aromatic C-H), 2915, 2853 (Aliphatic C-H), 1687, 1656 (C=O), 1610–1482 (C=C), 1258, 1224 (C-O). $^1\text{H-NMR}$ δ (ppm): 2.35 (3H, s, CH_3), 3.91 (3H, s, OCH_3), 5.59 (2H, s, OCH_2), 6.87 (1H, s, $=\text{CH}-$), 7.10–7.16 (3H, m, Ar-H), 7.24 (2H, d, J: 8.50 Hz, Ar-H), 7.48 (2H, d, J: 8.0 Hz, Ar-H), 7.58–7.62 (2H, m, Ar-H), 8.09 (2H, d, J: 7.32 Hz, Ar-H). MS $[M + 1]^+$: m/z 401.

2-[4-(2-(4-Chlorophenyl)-2-oxoethoxy)benzylidene]-5-methylbenzofuran-3-one (D16)

IR (KBr) $\nu_{\max}$ (cm⁻¹): 3063, 3025 (Aromatic C–H), 2981, 2864 (Aliphatic C–H), 1704, 1685 (C=O), 1642–1481 (C=C), 1256, 1258 (C–O). ¹H-NMR δ (ppm): 5.68 (2H, s, OCH₂), 6.88 (1H, s, =CH–), 7.11–7.17 (3H, m, Ar-H), 7.34 (2H, d, J: 8.64 Hz, Ar-H), 7.48 (2H, d, J: 7.54 Hz, Ar-H), 7.63–7.67 (2H, m, Ar-H), 8.08 (2H, d, J: 8.32 Hz, Ar-H). MS [M + 1]⁺: m/z 404.5.

2-[3-(2-Phenyl-2-oxoethoxy)benzylidene]-6-methylbenzofuran-3-one (D17)

IR (KBr) $\nu_{\max}$ (cm⁻¹): 3052, 3037 (Aromatic C–H), 2944, 2876 (Aliphatic C–H), 1696, 1667 (C=O), 1587–1469 (C=C), 1288, 1224 (C–O). ¹H-NMR δ (ppm): 2.44 (3H, s, CH₃), 5.67 (2H, s, OCH₂), 6.88 (1H, s, =CH–), 7.12–7.15 (3H, m, Ar-H), 7.34 (2H, d, J: 7.85 Hz, Ar-H), 7.68 (2H, d, J: 7.88 Hz, Ar-H), 7.93–7.95 (3H, m, Ar-H), 8.08 (2H, d, J: 8.74 Hz, Ar-H). MS [M + 1]⁺: m/z 371.

2-[3-(2-(4-Methoxyphenyl)-2-oxoethoxy)benzylidene]-6-methylbenzofuran-3-one (D18)

IR (KBr) $\nu_{\max}$ (cm⁻¹): 3084, 3051 (Aromatic C–H), 2975, 2827 (Aliphatic C–H), 1694, 1661 (C=O), 1618–1478 (C=C), 1292, 1219 (C–O). ¹H-NMR δ (ppm): 2.44 (3H, s, CH₃), 3.88 (3H, s, OCH₃), 5.65 (2H, s, OCH₂), 6.89 (1H, s, =CH–), 6.91 (1H, d, J: 8.42 Hz, Ar-H), 7.13–7.17 (3H, m, Ar-H), 7.35 (1H, s, Ar-H), 7.62–7.65 (2H, m, Ar-H), 7.75 (1H, t, J: 7.48 Hz, Ar-H), 7.94 (1H, d, J: 8.84 Hz, Ar-H), 8.07 (2H, d, J: 7.29 Hz, Ar-H). MS [M + 1]⁺: m/z 401.

2-[3-(2-(4-Chlorophenyl)-2-oxoethoxy)benzylidene]-6-methylbenzofuran-3-one (D19)

IR (KBr) $\nu_{\max}$ (cm⁻¹): 3077, 3029 (Aromatic C–H), 2987, 2860 (Aliphatic C–H), 1705, 1681 (C=O), 1621–1476 (C=C), 1271, 1223 (C–O). ¹H-NMR δ (ppm): 2.46 (3H, s, CH₃), 5.68 (2H, s, OCH₂), 6.89 (1H, s, =CH–), 7.12–7.14 (3H, d, J: 8.85 Hz, Ar-H), 7.36 (1H, s, Ar-H), 7.65–7.80 (3H, m, Ar-H), 7.94 (2H, d, J: 8.74 Hz, Ar-H), 8.05 (2H, d, J: 8.47 Hz, Ar-H). MS [M + 1]⁺: m/z 404.5.

2-[4-(2-Phenyl-2-oxoethoxy)benzylidene]-6-methylbenzofuran-3-one (D20)

IR (KBr) $\nu_{\max}$ (cm⁻¹): 3066, 3032 (Aromatic C–H), 2975, 2844 (Aliphatic C–H), 1698, 1659 (C=O), 1598–1475 (C=C), 1285, 1234 (C–O). ¹H-NMR δ (ppm): 2.43 (3H, s, CH₃), 5.69 (2H, s, OCH₂), 6.86 (1H, s, =CH–), 7.09–7.13 (5H, m, Ar-H), 7.31 (1H, s, Ar-H), 7.65 (2H, d, J: 7.81 Hz, Ar-H), 7.93 (2H, d, J: 7.93 Hz, Ar-H), 8.02 (2H, d, J: 8.88 Hz, Ar-H). MS [M + 1]⁺: m/z 371.

2-[4-(2-(4-Methoxyphenyl)-2-oxoethoxy)benzylidene]-6-methylbenzofuran-3-one (D21)

IR (KBr) $\nu_{\max}$ (cm⁻¹): 3098, 3045 (Aromatic C–H), 2976, 2834 (Aliphatic C–H), 1698, 1659 (C=O), 1611–1477 (C=C), 1288, 1217 (C–O). ¹H-NMR δ (ppm): 2.45 (3H, s, CH₃), 3.87 (3H, s, OCH₃), 5.64 (2H, s, OCH₂), 6.88 (1H, s, =CH–), 7.03 (1H, d, J: 8.02 Hz, Ar-H), 7.12 (2H, d, J: 8.85 Hz, Ar-H), 7.31 (1H, s, Ar-H), 7.57–7.60 (2H, m, Ar-H), 7.71 (1H, t, J: 7.45 Hz, Ar-H), 7.92 (2H, d, J: 8.84 Hz, Ar-H), 8.08 (2H, d, J: 7.28 Hz, Ar-H). MS [M + 1]⁺: m/z 401.

2-[4-(2-(4-Chlorophenyl)-2-oxoethoxy)benzylidene]-6-methylbenzofuran-3-one (D22)

IR (KBr) $\nu_{\max}$ (cm⁻¹): 3077, 3029 (Aromatic C–H), 2987, 2860 (Aliphatic C–H), 1705, 1681 (C=O), 1621–1476 (C=C), 1271, 1223 (C–O). ¹H-NMR δ (ppm): 2.46 (3H, s, Ar-CH₃), 5.68 (2H, s, OCH₂), 6.89 (1H, s, =CH–), 7.12–7.14 (3H, d, J: 8.85 Hz, Ar-H), 7.36 (1H, s, Ar-H), 7.65–7.80 (3H, m, Ar-H), 7.94 (2H, d, J: 8.74 Hz, Ar-H), 8.05 (2H, d, J: 8.47 Hz, Ar-H). MS [M + 1]⁺: m/z 404.5.

2-[3-(2-Phenyl-2-oxoethoxy)benzylidene]-6-methoxybenzofuran-3-one (D23)

(KBr) $\nu_{\max}$ (cm⁻¹): 3074, 3056 (Aromatic C–H), 2968, 2845 (Aliphatic C–H), 1696, 1661 (C=O), 1605–1475 (C=C), 1269, 1224 (C–O). ¹H-NMR δ (ppm): 3.90 (3H, s, OCH₃), 5.66 (2H, s, OCH₂), 6.80 (1H, s, =CH–), 6.85–6.89 (2H, m, Ar-H), 7.07–7.15 (2H, m, Ar-H), 7.35 (1H, t, J: 7.74 Hz, Ar-H), 7.42 (2H, d, J: 8.05 Hz, Ar-H), 7.58–7.64 (2H, m, Ar-H), 7.67–7.71 (1H, m, Ar-H), 8.05 (2H, d, J: 8.04 Hz, Ar-H). MS [M + 1]⁺: m/z 387.

2-[3-(2-(4-Methylphenyl)-2-oxoethoxy)benzylidene]-6-methoxybenzofuran-3-one (D24)

(KBr) $\nu_{\max}$ (cm⁻¹): 3085, 3034 (Aromatic C–H), 2967, 2879 (Aliphatic C–H), 1701, 1669 (C=O), 1597–1473 (C=C), 1267, 1234 (C–O). ¹H-NMR δ (ppm): 2.47 (3H, s, CH₃), 3.90 (3H, s, OCH₃), 5.77 (2H, s, OCH₂), 6.84 (1H, s, =CH–), 6.88 (1H, d, J: 7.85 Hz, Ar-H), 6.95–7.02 (2H, m, Ar-H), 7.21 (2H, d, J: 7.86 Hz, Ar-H), 7.48–7.52 (2H, m, Ar-H), 7.91 (2H, d, J: 8.14 Hz, Ar-H), 8.15 (2H, d, J: 8.69 Hz, Ar-H). MS [M + 1]⁺: m/z 401.

2-[3-(2-(4-Methoxyphenyl)-2-oxoethoxy)benzylidene]-6-methoxybenzofuran-3-one (D25)

(KBr) $\nu_{\max}$ (cm⁻¹): 3095, 3030 (Aromatic C–H), 2961, 2857 (Aliphatic C–H), 1702, 1668 (C=O), 1585–1484 (C=C), 1274, 1232 (C–O). ¹H-NMR δ (ppm): 3.89 (3H, s, OCH₃), 5.76 (2H, s, OCH₂), 6.83 (1H, s, =CH–), 6.86 (1H, dd, J: 2.02 ve 1.95 Hz, J: 8.55 Hz, Ar-H), 6.77–6.98 (1H, m, Ar-H), 7.15–7.21 (3H, m, Ar-H), 7.45 (1H, t, J: 8.05 ve 8.24 Hz, Ar-H), 7.59–7.61 (2H, m, Ar-H), 7.88–8.01 (2H, m, Ar-H), 8.22 (2H, d, J: 8.68 Hz, Ar-H). MS [M + 1]⁺: m/z 417.1.

2-[3-(2-(4-Chlorophenyl)-2-oxoethoxy)benzylidene]-6-methoxybenzofuran-3-one (D26)

(KBr) $\nu_{\max}$ (cm⁻¹): 3074, 3038 (Aromatic C–H), 2954, 2887 (Aliphatic C–H), 1702, 1667 (C=O), 1585–1454 (C=C), 1268, 1252 (C–O). ¹H-NMR δ (ppm): 3.91 (3H, s, OCH₃), 5.78 (2H, s, OCH₂), 6.85 (1H, s, =CH–), 6.94–7.05 (2H, m, Ar-H), 7.12–7.18 (3H, m, Ar-H), 7.45 (2H, d, J: 7.85 Hz, Ar-H), 7.88 (2H, d, J: 8.22 Hz, Ar-H), 8.13 (2H, d, J: 8.53 Hz, Ar-H). MS [M + 1]⁺: m/z 420.6.

2-[3-(2-(4-Nitrophenyl)-2-oxoethoxy)benzylidene]-6-methoxybenzofuran-3-one (D27)

(KBr) $\nu_{\max}$ (cm⁻¹): 3088, 3055 (Aromatic C–H), 2972, 2831 (Aliphatic C–H), 1697, 1659 (C=O), 1612–1477 (C=C, N=O), 1288, 1217 (C–O). ¹H-NMR δ (ppm): 3.89 (3H, s, OCH₃), 5.64 (2H, s, OCH₂), 6.81 (1H, s, =CH–), 6.85–6.89 (2H, d, J: 8.85 Hz, Ar-H), 7.07 (1H, dd, J: 1.37 Hz, J: 8.23 Hz, Ar-H), 7.32 (1H, t, J: 7.67 Hz, Ar-H), 7.38–7.43 (2H, m, Ar-H), 7.52–7.53 (2H, m, Ar-H), 7.67–7.71 (1H, m, Ar-H), 7.98 (2H, d, J: 8.03 Hz, Ar-H). MS [M + 1]⁺: m/z 432.1.

2-[4-(2-Phenyl-2-oxoethoxy)benzylidene]-6-methoxybenzofuran-3-one (D28)

(KBr) $\nu_{\max}$ (cm⁻¹): 3048, 3063 (Aromatic C–H), 2948, 2838 (Aliphatic C–H), 1697, 1663 (C=O), 1606–1454 (C=C), 1252, 1228 (C–O). ¹H-NMR δ (ppm): 3.91 (3H, s, OCH₃), 5.67 (2H, s, OCH₂), 6.81 (1H, s, =CH–), 6.94–7.02 (3H, m, Ar-H), 7.35 (2H, d, J: 7.78 Hz, Ar-H), 7.51 (2H, d, J: 8.05 Hz, Ar-H), 7.62–7.67 (2H, m, Ar-H), 7.67 (1H, s, Ar-H), 8.08 (2H, d, J: 8.06 Hz, Ar-H). MS [M + 1]⁺: *m/z* 387.

2-[4-(2-(4-Methylphenyl)-2-oxoethoxy)benzylidene]-6-methoxybenzofuran-3-one (D29)

(KBr) $\nu_{\max}$ (cm⁻¹): 3072, 3045 (Aromatic C–H), 2977, 2885 (Aliphatic C–H), 1702, 1668 (C=O), 1585–1456 (C=C), 1255, 1241 (C–O). ¹H-NMR δ (ppm): 2.48 (3H, s, CH₃), 3.91 (3H, s, OCH₃), 5.76 (2H, s, OCH₂), 6.85 (1H, s, =CH–), 6.98–7.05 (2H, m, Ar-H), 7.24 (2H, d, J: 7.86 Hz, Ar-H), 7.49–7.53 (3H, m, Ar-H), 7.94 (2H, d, J: 8.24 Hz, Ar-H), 8.16 (2H, d, J: 8.28 Hz, Ar-H). MS [M + 1]⁺: *m/z* 401.

2-[4-(2-(4-Methoxyphenyl)-2-oxoethoxy)benzylidene]-6-methoxybenzofuran-3-one (D30)

(KBr) $\nu_{\max}$ (cm⁻¹): 3098, 3032 (Aromatic C–H), 2965, 2844 (Aliphatic C–H), 1704, 1665 (C=O), 1598–1475 (C=C), 1285, 1227 (C–O). ¹H-NMR δ (ppm): 3.91 (3H, s, OCH₃), 5.75 (2H, s, OCH₂), 6.82 (1H, s, =CH–), 6.86 (1H, dd, J: 2.02, J: 8.55 Hz, Ar-H), 6.95–6.97 (1H, m, Ar-H), 7.11–7.14 (1H, m, Ar-H), 7.43 (1H, t, J: 8.05 ve 8.24 Hz, Ar-H), 7.59–7.61 (2H, m, Ar-H), 7.69 (1H, d, J: 8.56, Hz, Ar-H), 8.30 (2H, d, J: 8.73 Hz, Ar-H), 8.41 (2H, d, J: 8.68 Hz, Ar-H). MS [M + 1]⁺: *m/z* 417.1.

2-[4-(2-(4-Chlorophenyl)-2-oxoethoxy)benzylidene]-6-methoxybenzofuran-3-one (D31)

(KBr) $\nu_{\max}$ (cm⁻¹): 3041, 3027 (Aromatic C–H), 2932, 2873 (Aliphatic C–H), 1701, 1668 (C=O), 1580–1451 (C=C), 1253, 1242 (C–O). ¹H-NMR δ (ppm): 3.90 (3H, s, OCH₃), 5.77 (2H, s, OCH₂), 6.86 (1H, s, =CH–), 6.94 (1H, d, J: 7.85 Hz, Ar-H), 7.14 (1H, d, J: 7.89 Hz, Ar-H), 7.19–7.24 (2H, m, Ar-H), 7.45 (2H, d, J: 7.85 Hz, Ar-H), 7.54 (1H, d, J: 8.02 Hz, Ar-H), 7.88 (2H, d, J: 8.22 Hz, Ar-H), 8.13 (2H, d, J: 8.53 Hz, Ar-H). MS [M + 1]⁺: *m/z* 420.6.

2-[4-(2-(4-Nitrophenyl)-2-oxoethoxy)benzylidene]-6-methoxybenzofuran-3-one (D32)

(KBr) $\nu_{\max}$ (cm⁻¹): 3084, 3057 (Aromatic C–H), 2952, 2868 (Aliphatic C–H), 1698, 1658 (C=O), 1603–1474 (C=C, N=O), 1275, 1226 (C–O). ¹H-NMR δ (ppm): 3.89 (3H, s, OCH₃), 5.64 (2H, s, OCH₂), 6.81 (1H, s, =CH–), 7.10–7.16 (2H, m, Ar-H), 7.38 (2H, d, J: 8.23 Hz, Ar-H), 7.77 (2H, d, J: 7.68, Ar-H), 7.85–7.89 (2H, m, Ar-H), 7.94–7.96 (1H, m, Ar-H), 8.31 (1H, d, J: 8.03 Hz, Ar-H). MS [M + 1]⁺: *m/z* 432.1.

2-[3-(2-Phenyl-2-oxoethoxy)benzylidene]-5-chlorobenzofuran-3-one (D33)

IR (KBr) $\nu_{\max}$ (cm⁻¹): 3071, 3063 (Aromatic C–H), 2982, 2943, 2832 (Aliphatic C–H), 1701, 1665 (C=O), 1605–1458 (C=C), 1254, 1285 (C–O). ¹H-NMR δ (ppm): 5.67 (2H, s, OCH₂), 6.88 (1H, s, =CH–), 7.14 (1H, d, J: 8.18 Hz, Ar-H), 7.29 (1H, d, J: 8.75 Hz, Ar-H), 7.46 (2H, t, J: 8.10 Hz, Ar-H), 7.58–7.65 (3H, m, Ar-H), 7.74 (1H, t, J: 7.40 Hz, Ar-H), 7.89 (2H, d, J: 8.15 Hz, Ar-H), 8.12 (2H, d, J: 7.59 Hz, Ar-H). MS [M + 1]⁺: *m/z* 390.5.

2-[3-(2-(4-Methoxyphenyl)-2-oxoethoxy)benzylidene]-5-chlorobenzofuran-3-one (D34)

IR (KBr) $\nu_{\max}$ (cm⁻¹): 3072, 3035 (Aromatic C–H), 2953, 2839 (Aliphatic C–H), 1686, 1657 (C=O), 1623–1475 (C=C), 1284, 1242 (C–O). ¹H-NMR δ (ppm): 3.93 (3H, s, OCH₃), 5.62 (2H, s, OCH₂), 6.90 (1H, s, =CH–), 7.14 (2H, d, J: 8.42 Hz, Ar-H), 7.16 (2H, d, J: 8.51 Hz, Ar-H), 7.35 (2H, d, J: 8.19 Hz, Ar-H), 7.45 (1H, t, J: 8.24 Hz, Ar-H), 7.58–7.62 (2H, m, Ar-H), 8.14 (2H, d, J: 7.18 Hz, Ar-H). MS [M + 1]⁺: *m/z* 420.5.

2-[3-(2-(4-Chlorophenyl)-2-oxoethoxy)benzylidene]-5-chlorobenzofuran-3-one (D35)

IR (KBr) $\nu_{\max}$ (cm⁻¹): 3039, 3028 (Aromatic C–H), 2976, 2884 (Aliphatic C–H), 1701, 1683 (C=O), 1634–1482 (C=C), 1252, 1225 (C–O). ¹H-NMR δ (ppm): 5.67 (2H, s, OCH₂), 6.87 (1H, s, =CH–), 7.25 (1H, d, J: 8.14 Hz, Ar-H), 7.35 (2H, d, J: 8.74 Hz, Ar-H), 7.63 (1H, t, J: 7.46 Hz, Ar-H), 7.64–7.68 (3H, m, Ar-H), 7.76 (2H, d, J: 8.23 Hz, Ar-H), 8.24 (2H, d, J: 8.56 Hz, Ar-H). MS [M + 1]⁺: *m/z* 425.

2-[4-(2-Phenyl-2-oxoethoxy)benzylidene]-5-chlorobenzofuran-3-one (D36)

IR (KBr) $\nu_{\max}$ (cm⁻¹): 3055, 3027 (Aromatic C–H), 2977, 2951, 2846 (Aliphatic C–H), 1702, 1667 (C=O), 1606–1463 (C=C), 1265, 1294 (C–O). ¹H-NMR δ (ppm): 5.68 (2H, s, OCH₂), 6.89 (1H, s, =CH–), 7.15 (1H, d, J: 8.20 Hz, Ar-H), 7.33 (1H, d, J: 8.84 Hz, Ar-H), 7.52 (2H, t, J: 8.24 Hz, Ar-H), 7.67–7.76 (3H, m, Ar-H), 7.86 (1H, t, J: 7.85 Hz, Ar-H), 7.94 (2H, d, J: 8.21 Hz, Ar-H), 8.11 (2H, d, J: 7.63 Hz, Ar-H). MS [M + 1]⁺: *m/z* 390.5.

2-[4-(2-(4-Methoxyphenyl)-2-oxoethoxy)benzylidene]-5-chlorobenzofuran-3-one (D37)

IR (KBr) $\nu_{\max}$ (cm⁻¹): 3072, 3035 (Aromatic C–H), 2953, 2839 (Aliphatic C–H), 1686, 1657 (C=O), 1623–1475 (C=C), 1284, 1242 (C–O). ¹H-NMR δ (ppm): 3.93 (3H, s, OCH₃), 5.62 (2H, s, OCH₂), 6.90 (1H, s, =CH–), 7.14 (2H, d, J: 8.42 Hz, Ar-H), 7.16 (2H, d, J: 8.51 Hz, Ar-H), 7.35 (2H, d, J: 8.19 Hz, Ar-H), 7.45 (1H, t, J: 8.24 Hz, Ar-H), 7.58–7.62 (2H, m, Ar-H), 8.14 (2H, d, J: 7.18 Hz, Ar-H). MS [M + 1]⁺: *m/z* 420.5.

2-[4-(2-(4-Chlorophenyl)-2-oxoethoxy)benzylidene]-5-chlorobenzofuran-3-one (D38)

IR (KBr) $\nu_{\max}$ (cm⁻¹): 3056, 3038 (Aromatic C–H), 2984, 2897 (Aliphatic C–H), 1702, 1685 (C=O), 1635–1474 (C=C), 1236, 1227 (C–O). ¹H-NMR δ (ppm): 5.68 (2H, s, OCH₂), 6.88 (1H, s, =CH–), 7.29 (2H, d, J: 8.20 Hz, Ar-H), 7.55–7.64 (3H, m, Ar-H), 7.75 (2H, d, J: 8.12 Hz, Ar-H), 7.86 (2H, d, J: 8.12 Hz, Ar-H), 8.18 (2H, d, J: 8.27 Hz, Ar-H). MS [M + 1]⁺: *m/z* 425.

Anti-cancer activity

The cytotoxic and/or growth inhibitory effects of the compounds were evaluated *in vitro* against approximately sixty human tumor cell lines derived from nine neoplastic diseases namely; leukemia (L, 4 or 6 cell lines), non-small cell lung cancer (NSCLC, 9 cell lines), colon cancer (CC, 7 cell lines), central nervous system cancer (CNSC, 6 cell lines), melanoma (M, 8 or 9 cell lines), ovarian cancer (OC, 6 or 7 cell lines), renal cancer (RC, 8 cell lines), prostate cancer (PC, 2 cell lines), breast cancer (BC, 6 or 8 cell lines). The evaluation of anti-cancer activity was performed at the National Cancer Institute (NCI) of Bethesda, USA, following the *in vitro* screening program at 10-fold dilutions of five concentrations ranging from 10⁻⁴ to 10⁻⁸ M. The percentage growth was evaluated spectrophotometrically versus controls not

treated with test agents. A 48 h continuous drug exposure protocol was followed and a sulforhodamine B (SRB) protein assay was used to estimate cell viability of growth. Three dose response parameters (GI_{50} , TGI and LC_{50}) were calculated for each experimental agent^{47,48}.


Results and discussion

Chemistry


New aurone derivatives (**D1–D38**) were synthesized by an extensive synthetic procedure. Synthetic way for the compounds was outlined in Schemes 1, 2 and 3. Aurone synthesis is usually carried out with condensation reaction of benzofuranones and benzaldehydes and cyclization of various 2'-hydroxy aryl compounds⁴⁹. In this study, we also used condensation reaction and obtained 10 different aurone derivatives (**C1–C10**) from five benzofuranone derivatives (**A1–A4**, **B**) and final 38 compounds were gathered from these aurones derivatives. Benzofuranone derivatives (**A1–A4**, **B**) were synthesized in two different ways. Compounds **A1–A4** were acquired at the end of an extended and laborious synthetic procedure (Scheme 1). Initially, 2'-hydroxyacetophenone derivative was obtained and used as starting

material. For this, phenole derivative was primarily acetylated with acetic anhydride or acetyl chloride in pyridine, then the obtained acetyloxyphenol (**I**) derivative was heated at 160–170 °C in Fries conditions to get 2'-hydroxyacetophenone (**II**). This compound (**II**) was acetylated to protect phenolic hydroxyl group. Bromination of the obtained acetyloxyacetophenone (**III**) compound in acetic acid gave 2'-acetyloxy-2-bromoacetophenone (**IV**), which was then hydrolized with 10% HCl acid to afford 2'-hydroxy-2-bromoacetophenone (**V**). Eventually 5/6-substituted benzofuranone derivatives (**A1–A4**) were reached with the reaction of compound **V** and sodium acetate in ethanol via Williamson ether synthesis reaction.


As for 6-methoxybenzofuranone (**B**) compound, it was obtained by a three step reaction using resorcinol as a starting material (Scheme 2). In first step, 1,3-dihydroxybenzene was methylated with dimethylsulfate in basic medium to get 1,3-dimethoxybenzene. Second, according to Friedel–Crafts reaction, chloro acetyl group was linked to the aromatic ring when methoxy group on the *ortho* position of the carbonyl group including carbon loss of methyl radical with the effect of aluminium chloride and turn into phenolic hydroxyl. 6-Methoxybenzofuranone was gained from the obtained



Scheme 1. The synthesis of the benzofuran-3-one derivatives (**A1–A4**). Reactants/reagents and reaction conditions. a: $(\text{CH}_3\text{CO})_2\text{O}$, reflux, 30 min; b: AlCl_3 , 160–170 °C; c: $(\text{CH}_3\text{CO})_2\text{O}$, 50–100 °C, 3–4 h; d: Br_2 , HBr , diethyl ether or acetic acid; e: 10% HCl, reflux; f: CH_3COONa , EtOH, reflux.



Scheme 2. The synthesis of 6-methoxybenzofuranone (**B**). Reactants/reagents and reaction conditions. a: $(\text{CH}_3)_2\text{SO}_4$, NaOH, acetone, reflux, 4 h; b: AlCl_3 , CS_2 , dichloromethane, reflux, 30 min; c: CH_3COONa , EtOH, reflux.



Scheme 3. The synthesis of the final compounds (D1–D38). Reactants/reagents and reaction conditions. a: *n*-butanol/isobutanol, catalytic HCl, reflux, 1 h; b: acetone, K₂CO₃, reflux, 6 h.

Table 3. Sixty human tumor cell lines' anti-cancer screening data at single dose assay as percent cell growth promotion of selected compounds.

Com	NSCLC	CC	BC	OC	L	RC	M	PC	CNSC	Mean
D-2	94.50	108.37	124.84	105.53	81.24	83.22	115.04	111.98	107.64	102.25
D-3	95.50	112.32	92.64	98.69	77.72	93.86	106.45	109.78	93.22	97.16
D-5	88.83	103.21	82.68	100.07	74.30	100.28	99.02	98.90	109.49	94.76
D-8	91.01	103.28	91.17	100.10	91.10	85.04	96.47	108.69	108.71	95.76
D-9	102.86	103.02	101.92	103.84	95.51	101.78	103.90	108.37	135.51	105.83
D-10	102.20	124.04	116.29	129.25	101.45	100.06	102.47	109.20	114.76	113.99
D-14	87.21	101.61	94.51	97.39	113.88	98.59	92.88	107.45	96.06	97.28
D-17	91.82	98.69	91.41	104.45	72.27	97.85	90.17	230.58	97.49	97.76
D-23	90.93	87.06	80.34	101.09	72.06	95.71	103.25	110.97	113.84	95.03
D-27	93.94	96.15	93.85	94.13	92.49	96.67	99.96	97.86	84.96	94.47
D-28	99.40	113.57	135.62	105.58	86.41	96.76	113.30	107.18	116.13	108.32
D-30	99.58	111.34	100.96	95.91	82.68	112.45	103.37	113.69	101.56	102.09
D-32	98.87	106.82	104.76	100.76	89.24	98.86	103.19	122.53	99.78	101.21
D-37	86.58	89.17	85.26	85.01	49.47	101.78	89.21	107.41	94.49	86.23

NSCLC, non-small cell lung cancer; CC, colon cancer; BC, breast cancer; OC, ovarian cancer; L, leukemia; RC, renal cancer; M, melanoma; PC, prostate cancer; CNSC, central nervous system cancer.

2'-hydroxy-4'-methoxy-2-chloroacetophenone compound with ring closure reaction in Williamson ether synthesis conditions in third step.

2-(3- or 4-Hydroxybenzylidene)benzofuran-3-one derivatives (**C1–C10**) were formed with the reaction of ketone compounds (**A1–A4**, **B**) and 3-/4-hydroxybenzaldehydes according to Claisen-Schmidt condensation. Finally, final 2-[3- or 4-(2-aryl-2-oxoethoxy)arylidene]benzofuran-3-one compounds (**D1–D38**) were achieved with the reaction of brominated acetophenones and 2-(3- or 4-hydroxybenzylidene)benzofuran-3-one derivatives (**C1–C10**) according to S_N2 nucleophilic substitution reaction (Scheme 3).

The melting points were determined and uncorrected for all new compounds. The reactions were carried out in 55–75% yield. The structures of the final compounds (**D1–D38**) were elucidated by using IR, ¹H-NMR and MS spectral data. In the IR spectra of the compounds, characteristic stretching bands were observed at 1649–1712, 1456–1647 and 1217–1288 cm^{−1} due to C=O, C=C and C–O bonds. In double bond region, two bands were seen belonging to two carbonyl group which are on third position of benzofuranone ring and on benzoyl moiety. In the ¹H-NMR spectra, protons of acetyl residue were observed at about 5.62–5.79 ppm. The azomethine protons, –N=CH–, were resonated as singlets at about 6.81–6.99 ppm. All other aliphatic and aromatic protons were observed at expected regions. The aromatic

protons were seen at 6.85–8.43 ppm. The aurone derivatives are expected to be found mostly in both of *E* and *Z* isomerism and β-hydrogen atoms resonated ranged from 6.7 to 7.1 ppm. According to reported values for ¹H chemical shifts for (*Z*)-aurones (ca. 6.7 ppm) and (*E*)-aurones (ca. 7.2 ppm)⁵⁰, therefore the obtained final compounds are thought to be in (*Z*) isomerism. ES–MS spectra of the compounds gave confirmative molecular peaks.

All final compounds (**D1–D38**) were offered to NCI, USA for testing their anti-cancer activity according to drug screening protocol of the institute. Compounds **D2**, **D3**, **D5**, **D8**, **D9**, **D10**, **D14**, **D17**, **D23**, **D27**, **D28**, **D30**, **D32** and **D37** were selected by NCI for 60 human tumor cell lines' anti-cancer screening test at single dose assay. *In vitro* single dose anti-cancer assay was performed in full NCI 60 cell panel representing leukemia (L), non-small cell lung cancer (NSCLC), colon cancer (CC), central nervous system cancer (CNSC), melanoma (M), ovarian cancer (OC), renal cancer (RC), prostate cancer (PC), and breast cancer (BC). Results were given as percentage growth of the cancer diseases which were treated with selected compounds (Table 3, Supplementary material). As can be seen from Table 3, according to mean values, most of the compounds have affected primarily leukemia cell lines and compound **D37** exhibited the highest anti-tumor activity on leukemia cancer type with the growth percentage of 49.47%. Same compound showed the lowest mean growth

percentage among all tested compounds and it can be claimed as the most effective compound. HOP-92 (NSCLC) with 48.94%, HCT-116 (CC) with 23.58%, MCF7 (BC) with 47.13%, IGROV-1 (OC) with 32.85%, MOLT-4 (L) with –17.79% and SR (L) with –22.38% growth percentages were determined as the most susceptible cell lines against compound **D37**. Among all tumor cell lines, UO-31 which is renal cancer cell, has detected as the most sensitive one with growth percentages –37.07% against **D2**, –44.36% against **D8**, –29.24% against **D28**. Compound **D17** has also caused –34.25% growth percentage against MOLT-4 which is a leukemia cell line.

Conclusion

In this work, the synthesis of 2-[3- or 4-(2-aryl-2-oxoethoxy)arylidene]benzofuran-3-one derivatives (**D1–D38**) and anti-cancer activity of the selected compounds were investigated. The final compounds were obtained in a multistep synthetic procedure and the structures of the final compounds were proved using IR, ¹H-NMR and MS spectral data. According to anti-cancer activity results, compound **D8** exhibited the highest activity causing a growth percentage –44.36% on UO-31 cell line.

Acknowledgements

The authors present their thanks to NCI (USA) and Anadolu University BIBAM (Türkiye) for anti-cancer test results and NMR spectra, respectively.

Declaration of interest

This work was supported by Anadolu University, Turkey (BAP Project No: 050301). The authors report no conflicts of interest.

References

- Singh M, Kaur M, Silakari O. Flavones: an important scaffold for medicinal chemistry. *Eur J Med Chem* 2014;84:206–39.
- Cushnie TP, Lamb AJ. Antimicrobial activity of flavonoids. *Int J Antimicrob Agents* 2005;26:343–56.
- Detsi A, Majdalani M, Kontogiorgis CA, et al. Natural and synthetic 2'-hydroxy-chalcones and aurones: Synthesis, characterization and evaluation of the antioxidant and soybean lipoxygenase inhibitory activity. *Bioorg Med Chem* 2009;17:8073–85.
- Lewin G, Aubert G, Thoret S, et al. Influence of the skeleton on the cytotoxicity of flavonoids. *Bioorg Med Chem* 2012;20:1231–9.
- Fan R, Ban SR, Feng X, et al. Synthesis and anti-VSMC vegetation activities of new aurone derivatives. *Chem Res Chinese Universities* 2012;28:438–42.
- Venkateswarlu S, Panchagnula GK, Gottumukkala AD, Subbaraju GV. Synthesis, structural revision, and biological activities of 40-chloroaurone, a metabolite of marine brown alga *Spatoglossum variabile*. *Tetrahedron* 2007;63:6909–14.
- Mcalpine JB, Chu W-I A, Ratnayake S, et al. Antimicrobial aurone derivatives. *WO 1997026873 A1*, 1997.
- Kumar R, Dubey RK, Dixit P, Arya S. Naturally occurring aurones and chromones- potential organic therapeutic agents improvising nutritional security. *Int J Innov Res Sci Eng Technol* 2014;3:8141–8.
- Kayser O, Kiderlen AF. Leishmanicidal activity of aurones. *Tokai J Exp Clin Med* 1999;23:423–6.
- Kayser O, Chen M, Kharazmi A, Kiderlen AFZ. Aurones interfere with *Leishmania* major mitochondrial fumarate reductase. *Naturforsch* 2002;57:717–20.
- Roussaki M, Lima SC, Kypreou AM, et al. Aurones: a promising heterocyclic scaffold for the development of potent antileishmanial agents. *Int J Med Chem* 2012;2012:1–8.
- Wang J, Wang N, Yao X, Kitanaka S. Structures and anti-histamine activity of chalcones & aurones compounds from *Bidens parviflora* Willd. *Asian J Trad Med* 2007;2:23–9.
- Bandgar BP, Patil SA, Korbadi BL, et al. Synthesis and biological evaluation of a novel series of 2,2-bisaminomethylated aurone analogues as anti-inflammatory and antimicrobial agents. *Eur Med Chem* 2010;45:3223–7.
- Jardosh H, Patel MP. Antimicrobial and antioxidant evaluation of new quinolone based aurone analogs. *Arabian J Chem* 2014. (in press).
- Morimoto M, Fukumoto H, Nozoe T, et al. Synthesis and insect antifeedant activity of aurones against *Spodoptera litura* larvae. *J Agric Food Chem* 2007;55:700–5.
- Zhang M, Xu XH, Cui Y, et al. Synthesis and herbicidal potential of substituted aurones. *Pest Manag Sci* 2012;68:1512–22.
- Gao X, Yang L, Shu L, et al. Aurone constituents from the flowers of *Rosa rugosa* and their biological activities. *Heterocycles* 2012;85:1925–31.
- Gao X-M, Yang L-Y, Huang X-Z, et al. Aurones and isoaurones from the flowers of *Rosa damascena* and their biological activities. *Heterocycles* 2013;87:583–9.
- Meguellati A, Ahmed Belkacem A, Yi W, et al. B-ring modified aurones as promising allosteric inhibitors of hepatitis C virus RNA-dependent RNA polymerase. *Eur Med Chem* 2014;80:579–92.
- Haudecoeur R, Ahmed Belkacem A, Yi W, et al. Discovery of naturally occurring aurones that are potent allosteric inhibitors of hepatitis C virus RNA-dependent RNA polymerase. *J Med Chem* 2011;54:5395–402.
- Gupta AK, Singh P, Sabarwal N. Rationalization of molecular descriptors of aurone analogs toward antimalarial activity. *Asian J Pharm Clin Res* 2014;7:186–92.
- Carrasco MP, Newton AS, Gonçalves L, et al. Probing the aurone scaffold against *Plasmodium falciparum*: design, synthesis and antimalarial activity. *Eur J Med Chem* 2014;80:523–34.
- Di Giovanni S, Borloz A, Urbain A, et al. In vitro screening assays to identify natural or synthetic acetylcholinesterase inhibitors: thin layer chromatography versus microplate methods. *Eur J Pharm Sci* 2008;33:109–19.
- Sheng R, Xu Y, Hu C, et al. Design, synthesis and AChE inhibitory activity of indanone and aurone derivatives. *Eur J Med Chem* 2009;44:7–17.
- Geldenhuis WJ, Funk MO, Van der Schyf CJ, Carroll RT. A scaffold hopping approach to identify novel monoamine oxidase B inhibitors. *Bioorg Med Chem Lett* 2012;22:1380–3.
- Nenadis N, Sigalas MP. A DFT study on the radical scavenging activity of maritimetin and related aurones. *J Phys Chem* 2008;112:12196–202.
- Shin SY, Shin MC, Shin JS, et al. Synthesis of aurones and their inhibitory effects on nitric oxide and PGE2 productions in LPS-induced RAW 264.7 cells. *Bioorg Med Chem Lett* 2011;21:4520–3.
- Lee YR, Hwang JK, Koh HW, et al. Sulfuretin, a major flavonoid isolated from *Rhus verniciflua*, ameliorates experimental arthritis in mice. *Life Sci* 2012;90:799–807.
- Huang W, Liu MZ, Li Y, et al. Design, synthesis, and antitumor activity of novel chromone and aurone derivatives. *Bioorg Med Chem* 2007;15:5191–7.
- Schoepfer J, Fretz H, Chaudhuri B, et al. Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics. *J Med Chem* 2002;25:1741–7.
- Boumendjel A. Aurones: a subclass of flavones with promising biological potential. *Curr Med Chem* 2003;10:2621–30.
- Dubois C, Haudecoeur R, Orio M, et al. Versatile effects of aurone structure on mushroom tyrosinase activity. *Chem Bio Chem* 2012;13:559–65.
- Parate A, Sharma R, Maheshwari I. Structural indents for 5-hydroxyaurone derivatives as potent anticancer agents against HUVEC cancer cell lines-kNN MFA approach. *Der Pharmacia Sinica* 2013;4:121–9.
- Zwergel C, Valente S, Salvato A, et al. Novel benzofuran–chromone and –coumarin derivatives: synthesis and biological activity in K562 human leukemia cells. *Med Chem Commun* 2013;4:1571–9.
- Cheng H, Zhang L, Liu Y, et al. The total design, synthesis and discovery of 5-hydroxyaurone derivatives as growth inhibitors against HUVEC and some cancer cell lines. *Eur J Med Chem* 2010;45:5950–7.
- Okombi S, Rival D, Bonnet S, et al. Discovery of benzylidene-benzofuran-3(2h)-one (aurones) as inhibitors of tyrosinase derived from human melanocytes. *J Med Chem* 2006;49:329–33.
- Lawrence NJ, Rennison D, McGown AT, Hadfield JA. The total synthesis of an aurone isolated from *Uvaria hamiltonii*: aurones and

- flavones as anticancer agents. *Bioorg Med Chem Lett* 2003;13: 3759–63.
38. Zheng X, Wang H, Liu YM, et al. Synthesis, characterization, and anticancer effect of trifluoromethylated aurone derivatives. *J Heterocyclic Chem* 2014. (in press).
39. Ballinari D, Bonomini L, Ermoli A, et al. *Chem. Abst.* CA2441274A1. WO2002083123 A1, 2002.
40. Pratt WB, Ruddon RW, Ensminger WD. *The anticancer drugs*. New York: Oxford University Press; 1994:69–198.
41. Rajski SC, Williams RM. DNA cross-linking agents as antitumor drugs. *Chem Rev* 1998;98:2723–96.
42. Demirayak S, Yurttaş L. Synthesis and anticancer activity of some 1,2,3-trisubstituted pyrazinobenzimidazole derivatives. *J Enzyme Inhib Med Chem* 2014. (in press).
43. Gundogdu Karaburun N, Karaburun AC, Demirayak S, et al. Synthesis and anticancer activity of some 2-[3/4-(2-substituted phenyl-2-oxoethoxy)benzylidene]-6-substituted-2,3-dihydro-1H-inden-1-one derivatives. *Lett Drug Des Discov* 2014;11:578–85.
44. Sousa CM, Berthet J, Delbaere S, Coelho PJ. One pot synthesis of aryl substituted aurones. *Dyes Pigments* 2011;92:537–41.
45. Thakkar K, Cushman M. A novel oxidative cyclization of 2'-hydroxychalcones to 4,5-dialkoxyaurones by thallium(III) nitrate. *J Org Chem* 1995;60:6499–6510.
46. Bose AK, Manhas MS, Ghosh M, et al. Microwave-induced organic reaction enhancement chemistry. 2. Simplified techniques. *J Org Chem* 1991;56:6968–70.
47. Higginbotham L, Stephen H. Coumarone Series. I. The preparation of 4-, 5- and 6-methylcoumaran-2-ones and some derivate of o-, m- and p-tolyloxyacetic acids. *J Am Chem Soc* 1920;117:1534–42.
48. Balakrishna KJ, Rao NP, Seshadri TR. A method of distinguishing between flavones and flavonols. *Proc Indian Natl Sci Acad A* 1949; 29A:394–403.
49. Geissman TA, Harborne JB. Anthochlor pigments. XIII. The ultraviolet absorption spectra of phenolic plant pigments. polyhydroxyaurones. *J Am Chem Soc* 1956;78:832–7.
50. Dean FM, Podimuang V. The course of the Algar-Flynn-Oyamada (A.F.O.) reaction. *J. Chem Soc* 1965:3978–87.
51. Goldsack RJ, Shannon JS. Proximity effects in the electron impact mass spectra of aurones and related compounds. *Org Mass Spectrometr* 1980;15:545–55.
52. Boyd MR. Status of the NCI preclinical antitumor drug discovery screen, principles and practice of oncology. *Princip Prac Oncol* 1989;3:1–42.
53. Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. *Drug Dev Res* 1995;34:91–109.

Supplementary material available online
Supplementary data